Deep Brain TMS for Bipolar Depression

This is a multicenter, randomized, double-blind study to evaluate the efficacy and safety of H1-Coil deep brain rTMS in subjects with bipolar depression, taking mood stabilizers and previously unsuccessfully treated with antidepressant medications. The study is designed for a period of eight weeks of which up to three weeks subjects will be tapered down from their medications and treated for five weeks. Two follow up visits will be performed at week six and eight after the last TMS treatment. Mood and mental status will be closely monitored with standard psychological scales and assessments. One would be eligible for this study if s/he is between the age of 22 and 68, suffering from an episode of depression for at least four weeks, has no history of seizures or adverse events to TMS, and is taking a therapeutic dose of mood stabilizing medication (e.g., Lithium, Lamictal, Tegretol, Topamax, etc.) or atypical antipsychotic medication which was prescribed as mood stabilizers by their treating physician.

Contact Information:
Principle Investigator: Dan V. Iosifescu
Study Cordinator: Roya Nazarian
Tel: 212-241-3089
E-mail: roya.nazarian@mssm.edu

Recruiting Patients: Yes

Address:
Atran Berg Laboratory Building
Floor E Level
1428 Madison Avenue
New York, NY 10029